ReviewFrontiers in oncology2023
The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials.
A Fisher et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
ReviewFrontiers in oncology2023
A Fisher et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.